| Entry |
|
|---|
| Name |
Solriamfetol hydrochloride (USAN);
Sunosi (TN)
|
|---|
| Product |
|
|---|
| Formula |
C10H14N2O2. HCl
|
|---|
| Exact mass |
230.0822
|
|---|
| Mol weight |
230.6913
|
|---|
| Structure |
   |
|---|
| Simcomp |
 |
|---|
| Remark |
| Product (DG02989): | D11328<US> |
|
|---|
| Efficacy |
Wake-promoting agent, Noradrenalin and dopamine reuptake inhibitor |
|---|
| Disease |
|
|---|
| Comment |
Wake-promoting agent for the treatment of excessive sleepiness associated with narcolepsy or obstructive sleep apnea
|
|---|
| Target |
|
|---|
| Pathway |
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
N NERVOUS SYSTEM
N06 PSYCHOANALEPTICS
N06B PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS
N06BA Centrally acting sympathomimetics
N06BA14 Solriamfetol
D11328 Solriamfetol hydrochloride (USAN) <US>
USP drug classification [BR:br08302]
Sleep Disorder Agents
Wakefulness Promoting Agents
Solriamfetol
D11328 Solriamfetol hydrochloride (USAN)
Target-based classification of drugs [BR:br08310]
Transporters
Solute carrier family
SLC6
SLC6A2 (NAT1)
D11328 Solriamfetol hydrochloride (USAN) <US>
SLC6A3 (DAT1)
D11328 Solriamfetol hydrochloride (USAN) <US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D11328
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D11328
 |
|---|
| Other DBs |
|
|---|
| LinkDB |
 |
|---|
| KCF data |
ATOM 15
1 C8x C 13.7981 -16.1795
2 C8x C 13.7981 -17.5803
3 C8x C 15.0589 -18.2807
4 C8x C 16.2496 -17.5803
5 C8y C 16.2496 -16.1795
6 C8x C 15.0589 -15.4791
7 C1b C 17.5103 -15.4791
8 C1c C 18.7010 -16.1795
9 C1b C 19.8917 -15.4791
10 O7a O 21.0824 -16.1795
11 C7a C 22.2731 -15.4791
12 N1a N 23.4638 -16.1795
13 O6a O 22.2731 -14.0783
14 N1a N 18.7010 -17.5803
15 X Cl 26.6000 -18.2000
BOND 14
1 1 2 2
2 2 3 1
3 3 4 2
4 4 5 1
5 5 6 2
6 1 6 1
7 5 7 1
8 7 8 1
9 8 9 1
10 9 10 1
11 10 11 1
12 11 12 1
13 11 13 2
14 8 14 1 #Down
|
|---|
